ITOS vs. REPL, ADPT, TCRX, TRML, AURA, LXEO, JSPR, TNYA, VYGR, and EDIT
Should you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Replimune Group (REPL), Adaptive Biotechnologies (ADPT), TScan Therapeutics (TCRX), Tourmaline Bio (TRML), Aura Biosciences (AURA), Lexeo Therapeutics (LXEO), Jasper Therapeutics (JSPR), Tenaya Therapeutics (TNYA), Voyager Therapeutics (VYGR), and Editas Medicine (EDIT). These companies are all part of the "biological products, except diagnostic" industry.
iTeos Therapeutics (NASDAQ:ITOS) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.
iTeos Therapeutics has higher revenue and earnings than Replimune Group. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.
iTeos Therapeutics' return on equity of -18.40% beat Replimune Group's return on equity.
97.2% of iTeos Therapeutics shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 10.2% of iTeos Therapeutics shares are held by company insiders. Comparatively, 20.6% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
iTeos Therapeutics currently has a consensus target price of $30.33, indicating a potential upside of 73.93%. Replimune Group has a consensus target price of $37.67, indicating a potential upside of 487.62%. Given Replimune Group's higher possible upside, analysts plainly believe Replimune Group is more favorable than iTeos Therapeutics.
iTeos Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.
Replimune Group received 123 more outperform votes than iTeos Therapeutics when rated by MarketBeat users. However, 72.50% of users gave iTeos Therapeutics an outperform vote while only 61.54% of users gave Replimune Group an outperform vote.
In the previous week, iTeos Therapeutics had 7 more articles in the media than Replimune Group. MarketBeat recorded 8 mentions for iTeos Therapeutics and 1 mentions for Replimune Group. iTeos Therapeutics' average media sentiment score of 0.09 beat Replimune Group's score of 0.00 indicating that iTeos Therapeutics is being referred to more favorably in the media.
Summary
iTeos Therapeutics beats Replimune Group on 10 of the 14 factors compared between the two stocks.
Get iTeos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iTeos Therapeutics Competitors List
Related Companies and Tools
